Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia

被引：87
作者：
Dahabreh, Issa J. [1 ,2 ]
Zoi, Katerina [2 ]
Giannouli, Stavroula [1 ]
Zoi, Christine [1 ,2 ]
Loukopoulos, Dirnitrios [2 ]
Voulgarelis, Michael [1 ]
机构：
[1] Natl Tech Univ Athens, Sch Med, Dept Pathophysiol, Athens 11527, Greece
[2] Acad Athens, Biomed Res Fdn, Hemmatol Res Lab, Athens, Greece
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷 / 01期
关键词：
Essential thrombocythemia; JAK2; V617F; Thrombosis; Systematic review; Meta-analysis; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE-DISORDERS; ALLELE BURDEN; RISK-FACTORS; 617V-GREATER-THAN-F MUTATION; JAK2(V617F) MUTATION; LEUKOCYTE ACTIVATION; JAK2-V617F MUTATION; THROMBOSIS; MYELOFIBROSIS;
D O I：
10.1016/j.leukres.2008.06.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A systematic review and meta-analysis was carried out to compare the frequency of clinically significant outcomes between JAK2 V617F positive and wild type patients with essential thrombocythemia (ET). JAK2 V617F positivity in patients with ET was associated with a clear increase in the odds of thrombosis [OR = 1.83 (95% CI, 1.32-2.53), p < 0.0001], and much higher odds of transformation to polycythemia vera [OR = 7.67 (95% Cl, 2.04-28.87), p = 0.0009]. The mean difference of the white blood cell count between JAK2 positive and negative patients was associated with an increased odds ratio for thrombosis (p = 0.02). The JAK2 V617F mutation in patients with ET is associated with an increased risk of adverse cardiovascular outcomes via an increase in the leukocyte count. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码：67 / 73
页数：7
相关论文
共 52 条
[1]   JAK2V617F mutation in Korean patients with essential thrombocythemia [J].
Ahn, Jeong-Yeal ;
Yoo, Soo-Jin ;
Bang, Soo-Mee ;
Park, Pil-Whan ;
Seo, Yiel-Hea ;
Shin, Dong-Bok ;
Lee, Jae-Hoon .
KOREAN JOURNAL OF LABORATORY MEDICINE, 2007, 27 (02) :77-82
[2]   Statistics Notes - Interaction revisited: the difference between two estimates [J].
Altman, DG ;
Bland, JM .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7382) :219-219
[3]   Essential thrombocythemia in young individuals:: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients [J].
Alvarez-Larran, A. ;
Cervantes, F. ;
Bellosillo, B. ;
Giralt, M. ;
Julia, A. ;
Hernandez-Boluda, J. C. ;
Bosch, A. ;
Hernandez-Nieto, L. ;
Clapes, V. ;
Burgaleta, C. ;
Salvador, C. ;
Arellano-Rodrigo, E. ;
Colomer, D. ;
Besses, C. .
LEUKEMIA, 2007, 21 (06) :1218-1223
[4]  
Andrikovics Hajnalka, 2007, Orv Hetil, V148, P203, DOI 10.1556/OH.2007.27860
[5]   Clinical implications of the JAK2 V617F mutation in essential thrombocythemia [J].
Antonioli, E ;
Guglielmelli, P ;
Pancrazzi, A ;
Bogani, C ;
Verrucci, M ;
Ponziani, V ;
Longo, G ;
Bosi, A ;
Vannucchi, AM .
LEUKEMIA, 2005, 19 (10) :1847-1849
[6]   Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia [J].
Antonioli, Elisabetta ;
Guglielmelli, Paola ;
Poli, Giada ;
Bogani, Costanza ;
Pancrazzi, Alessandro ;
Longo, Giovanni ;
Ponziani, Vanessa ;
Tozzi, Lorenzo ;
Pieri, Lisa ;
Santini, Valeria ;
Bosi, Alberto ;
Vannucchi, Alessandro M. .
HAEMATOLOGICA, 2007, 93 (01) :41-48
[7]  
Arellano-Rodrigo E, 2006, HAEMATOL-HEMATOL J, V91, P169
[8]   When and how to treat essential thrombocythemia [J].
Barbui, T ;
Finazzi, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (01) :85-86
[9]   Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk [J].
Barbui, Tiziano ;
Finazzi, Guido .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (04) :321-329
[10]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
123456